

**Closed Session Minutes**  
**of the**  
**Maryland Commission on Kidney Disease**  
**April 21, 2016**

Upon motion made in public session, Chairman Gimenez called for adjournment of the Public Session into closed session to discuss the following item:

1. Legal Consultation on the Request by Veloxis to Add Envarsus XR to the KDP Formulary.

The Closed Session was called to order at 4:07 p.m. and held under the authority of § 3-104 of the General Provisions Article.

In attendance, in addition to Chairman Gimenez, were Commissioners' Collins, Jaar, Kraus, Leon, Rayfield, Wise, and Yospin were present.

In attendance representing Staff was Eva Schwartz, Executive Director and Donna Adcock, RN, Surveyor.

Also attending was Leslie Schulman, Commission Counsel.

**Item One**

The Commission discussed the request by Veloxis to approve adding Envarsus XR to the Kidney Disease Program's Formulary. After discussion lead by Dr. Kraus concerning the clinical benefits and cost factors in comparison to the other approved immunosuppressant formulary drugs, the Commission unanimously voted to approve adding Envarsus XR to the formulary. Counsel advised the Commission that ratification of the vote will take place at the next Public Session. (Authority: General Provisions Article, § 3-305 (b)(7))

Upon Motion made, the Closed Session was adjourned at 4:24 p.m.